Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase NA 2Phase 2 2Phase 1/2 2

Status

Terminated 2Completed 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Brain Neoplasms 2Neoplasms 1Lymphoma 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × alovudine × Clear all
NCT03276676 2024-12-27

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

University of Utah

Phase 1/2 Terminated
10 enrolled 7 charts
CNS

Brain Neoplasms

NCT01065805 2019-08-22

A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

AHS Cancer Control Alberta

Phase 1/2 Terminated
94 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡